Safety and Tolerability of Low-dose Naltrexone Therapy in Children with Moderate to Severe Crohn's Disease: a Pilot Study

Overview

Journal J Clin Gastroenterol

Specialty Gastroenterology

Date 2012 Nov 29

PMID 23188075

Citations 17

Authors

Jill P Smith

Douglas Field

Sandra I Bingaman

Robert Evans

David T Mauger

Affiliations

Soon will be listed here.

Abstract

Background: There is an unmet need for safe and effective medicines to treat children with Crohn's disease. Recently, investigations have shown an association between endogenous opioid peptides and inflammatory cells.

Aims: The aims of this study were to evaluate the safety and tolerability of an opioid antagonist, naltrexone, in children with moderate to severe Crohn's disease.

Methods: A pilot clinical trial was conducted in children with moderate to severe Crohn's disease. Fourteen subjects with a mean age of 12.3 years (range, 8 to 17 y) were enrolled. Children were randomized to placebo or naltrexone (0.1 mg/kg) orally for 8 weeks followed by open-labeled treatment with 8 additional weeks of naltrexone. Safety and toxicity were monitored by physical examinations and blood chemistries. Clinical activity was assessed by the Pediatric Crohn's Disease Activity Index (PCDAI) and Quality of life was monitored by the Impact III survey.

Results: Oral naltrexone was well tolerated without any serious adverse events in children with moderate to severe Crohn's disease. PCDAI scores significantly decreased from pretreatment values (34.2±3.3) with an 8-week course of naltrexone therapy (21.7±3.9) (P=0.005). Twenty-five percent of those treated with naltrexone were considered in remission (score ≤10) and 67% had improved with mild disease activity (decrease in PCDAI score by at least 10 points) at the end of the study. Systemic and social quality of life improved with naltrexone treatment (P=0.035).

Conclusions: Naltrexone therapy seems safe with limited toxicity when given to children with Crohn's disease and may reduce disease activity.

Citing Articles

The Utilization of Low Dose Naltrexone for Chronic Pain.

Poliwoda S, Noss B, Truong G, Creech Z, Koushik S, Urits I CNS Drugs. 2023; 37(8):663-670.

PMID: 37505425 DOI: 10.1007/s40263-023-01018-3.

Low-dose naltrexone's utility for non-cancer centralized pain conditions: a scoping review.

Rupp A, Young E, Chadwick A Pain Med. 2023; 24(11):1270-1281.

PMID: 37302106 PMC: 10628981. DOI: 10.1093/pm/pnad074.

Use of Contrave, Naltrexone with Bupropion, Bupropion, or Naltrexone and Major Adverse Cardiovascular Events: A Systematic Literature Review.

Dahlberg S, Chang E, Weiss S, Dopart P, Gould E, Ritchey M Diabetes Metab Syndr Obes. 2022; 15:3049-3067.

PMID: 36200062 PMC: 9529009. DOI: 10.2147/DMSO.S381652.

Low-dose naltrexone for the induction of remission in patients with mild to moderate Crohn's disease: protocol for the randomised, double-blinded, placebo-controlled, multicentre LDN Crohn study.

Paulides E, Lie M, van der Woude C BMJ Open. 2022; 12(4):e058358.

PMID: 35396307 PMC: 8996009. DOI: 10.1136/bmjopen-2021-058358.

Developmental Considerations for the Use of Naltrexone in Children and Adolescents.

Stancil S, Abdel-Rahman S, Wagner J J Pediatr Pharmacol Ther. 2021; 26(7):675-695.

PMID: 34588931 PMC: 8475793. DOI: 10.5863/1551-6776-26.7.675.

References

Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J . Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007; 132(3):863-73. DOI: 10.1053/j.gastro.2006.12.003. View

Van Limbergen J, Russell R, Drummond H, Aldhous M, Round N, Nimmo E . Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008; 135(4):1114-22. DOI: 10.1053/j.gastro.2008.06.081. View

Raynor K, Kong H, Chen Y, Yasuda K, Yu L, Bell G . Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol Pharmacol. 1994; 45(2):330-4. View

Waldhoer M, Bartlett S, Whistler J . Opioid receptors. Annu Rev Biochem. 2004; 73:953-90. DOI: 10.1146/annurev.biochem.73.011303.073940. View

Griffiths A, Otley A, Hyams J, Quiros A, Grand R, Bousvaros A . A review of activity indices and end points for clinical trials in children with Crohn's disease. Inflamm Bowel Dis. 2005; 11(2):185-96. DOI: 10.1097/00054725-200502000-00013. View

McCarthy L, Wetzel M, Sliker J, Eisenstein T, Rogers T . Opioids, opioid receptors, and the immune response. Drug Alcohol Depend. 2001; 62(2):111-23. DOI: 10.1016/s0376-8716(00)00181-2. View

Mackey A, Green L, Liang L, Dinndorf P, Avigan M . Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007; 44(2):265-7. DOI: 10.1097/MPG.0b013e31802f6424. View

Eiser C, Morse R . Quality-of-life measures in chronic diseases of childhood. Health Technol Assess. 2001; 5(4):1-157. DOI: 10.3310/hta5040. View

Motil K, Grand R, Ferlic L, Smith E . Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology. 1993; 105(3):681-91. DOI: 10.1016/0016-5085(93)90883-e. View

10.

Matters G, Harms J, McGovern C, Fitzpatrick L, Parikh A, Nilo N . The opioid antagonist naltrexone improves murine inflammatory bowel disease. J Immunotoxicol. 2008; 5(2):179-87. DOI: 10.1080/15476910802131469. View

11.

Petrakis I, Ralevski E, Nich C, Levinson C, Carroll K, Poling J . Naltrexone and disulfiram in patients with alcohol dependence and current depression. J Clin Psychopharmacol. 2007; 27(2):160-5. DOI: 10.1097/jcp.0b13e3180337fcb. View

12.

Cross R, Wilson K, Binion D . Narcotic use in patients with Crohn's disease. Am J Gastroenterol. 2005; 100(10):2225-9. DOI: 10.1111/j.1572-0241.2005.00256.x. View

13.

Mitchell J . Naltrexone and hepatotoxicity. Lancet. 1986; 1(8491):1215. DOI: 10.1016/s0140-6736(86)91196-7. View

14.

Lichtenstein G, Feagan B, Cohen R, Salzberg B, Diamond R, Chen D . Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006; 4(5):621-30. DOI: 10.1016/j.cgh.2006.03.002. View

15.

Finley M, Happel C, Kaminsky D, Rogers T . Opioid and nociceptin receptors regulate cytokine and cytokine receptor expression. Cell Immunol. 2008; 252(1-2):146-54. PMC: 2538679. DOI: 10.1016/j.cellimm.2007.09.008. View

16.

Hawkes N, Rhodes J, Evans B, Rhodes P, Hawthorne A, Thomas G . Naloxone treatment for irritable bowel syndrome--a randomized controlled trial with an oral formulation. Aliment Pharmacol Ther. 2002; 16(9):1649-54. DOI: 10.1046/j.1365-2036.2002.01320.x. View

17.

Irvine E, Feagan B, Rochon J, Archambault A, Fedorak R, Groll A . Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology. 1994; 106(2):287-96. DOI: 10.1016/0016-5085(94)90585-1. View

18.

Kariv R, Tiomny E, Grenshpon R, Dekel R, Waisman G, Ringel Y . Low-dose naltreoxone for the treatment of irritable bowel syndrome: a pilot study. Dig Dis Sci. 2006; 51(12):2128-33. DOI: 10.1007/s10620-006-9289-8. View

19.

Underwood M, Bevins C . Defensin-barbed innate immunity: clinical associations in the pediatric population. Pediatrics. 2010; 125(6):1237-47. DOI: 10.1542/peds.2009-3289. View

20.

LLOYD-STILL J, GREEN O . A clinical scoring system for chronic inflammatory bowel disease in children. Dig Dis Sci. 1979; 24(8):620-4. DOI: 10.1007/BF01333706. View